CSV vs. CSA: What the FDA’s Guidance Actually Requires in Practice

Computer Software Assurance (CSA) has become one of the most talked about changes in life sciences validation. Yet despite the FDA issuing its guidance in 2022, and subsequently finalizing it, many organizations are still asking the same question: What actually changes?

For some, the answer has been to reduce documentation. Shorter protocols. Fewer test scripts. Leaner validation packages.

But CSA was never intended to be a shortcut.

The FDA's guidance doesn't lower expectations; it changes how organizations demonstrate confidence that software is fit for its intended use. Instead of measuring compliance by the volume of documentation produced, CSA encourages organizations to apply validation effort where it matters most: protecting patient safety, product quality, and data integrity.

That's where many organizations struggle. They change the paperwork before changing the decision-making process.

Computer System Validation (CSV) is the documented process of demonstrating that a computerized system consistently performs as intended and is suitable for its regulated GxP use.

For decades, CSV has been the foundation of software compliance across the life sciences industry. Validation activities are supported by FDA regulations governing GxP operations, including 21 CFR Part 11 for electronic records and electronic signatures, applicable GMP and Quality System regulations, EU Annex 11, and industry best practices such as ISPE GAMP® 5.

The objective has always been straightforward: provide documented evidence that computerized systems are fit for their intended use.

To accomplish this, organizations traditionally followed a structured validation lifecycle that included:

This lifecycle brought consistency to validation programs and created a common language between industry and regulators.

Computer System Validation has historically been supported by FDA regulations governing GxP computerized systems. That logic was coherent for its time. In an era of purpose-built, relatively static enterprise systems, exhaustive documentation of system behavior was a reasonable way to demonstrate control. The V-model gave validation teams a structured lifecycle. IQ/OQ/PQ gave regulators a consistent language. And the paper trail, however voluminous, gave organizations something concrete to point to during inspection.

The problem was not the logic. The problem was the execution.

Computer Software Assurance (CSA) is the FDA's risk-based approach for establishing confidence that production and quality system software is fit for its intended use.

That shift — from activity completion to confidence demonstration — sounds philosophical until you trace its operational implications.

CSA encourages organizations to focus validation activities on areas that could impact:

This is not a reduction in regulatory rigor. It is a redirection of regulatory effort toward the places where it actually matters.

The FDA was explicit on this point. CSA is not a pathway to doing less. It is a framework for doing the right things and for being able to explain to a regulator, precisely why those were the right things to do.

Although organizations often associate CSA with reducing documentation, the FDA guidance is fundamentally built around three principles.

One of the most common questions quality and validation professionals ask is: Is CSA replacing Computer System Validation?

The short answer is no. Organizations are still responsible for validating computerized systems used in regulated environments. But several critical misconceptions about what CSA does and does not permit are creating real compliance exposure.

The most dangerous position in the CSV-to-CSA transition is the one most organizations are currently in: partially transitioned.

A partial transition typically looks like this. The organization reduces its protocol burden — fewer test scripts, shorter execution cycles, less IQ/OQ documentation. It tells its team that it is following a risk-based approach. But it has not built the risk categorization framework that makes scope decisions defensible. It has not trained its validation engineers on how to construct and document a critical thinking record. It has not updated its QMS to support CSA-style periodic review instead of change-triggered revalidation. And it has not updated its supplier qualification process to capture the evaluation of vendor documentation rather than its reproduction.

The result is a program that has neither the exhaustive documentation trail of CSV to fall back on nor the documented risk rationale of CSA to justify reduced scope. It has reduced its paper without replacing it with thinking, and a regulator who asks why a particular function was not tested will find no answer.

This is the transition trap. And it is where many life sciences organizations currently sit.

Avoiding it requires treating CSA as an organizational change, not a documentation policy change. It requires updating SOPs, retraining validation teams, building new document templates, revising supplier qualification procedures, and establishing a periodic review cadence that actually executes.

An organization that has genuinely transitioned to CSA can demonstrate the following to a regulator:

Before your next audit or inspection, your team should be able to answer yes to each of the following:

If any of these questions surface uncertainty, the gap between your current program and a genuinely audit-ready CSA framework is worth closing before a regulator identifies it.

At AVS Life Sciences, we work with quality and validation teams that are navigating exactly this transition — organizations that have committed to CSA in principle and need the operational architecture to execute it in practice.

We build the frameworks that make CSA defensible: risk categorization systems calibrated to your specific software environment, critical thinking record templates that capture the rationale regulators want to see, supplier evaluation processes that allow you to leverage vendor documentation without accepting it uncritically, and periodic review cadences that maintain the compliance record your validated systems require.

For organizations that have already started the transition and are uncertain about where the gaps are, we provide structured gap assessments that map your current program against CSA requirements and identify the specific SOPs, templates, and training investments needed to close them.

The organizations that benefit most from CSA are not the ones that used it to do less. They are the ones that used it to think more clearly about where validation effort actually protects patient safety and data integrity — and directed their resources accordingly.